Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. We are a leader in the renal community – a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization.
We have a portfolio focused on addressing significant unmet needs for people living with kidney disease.
RESEARCH & DEVELOPMENT
November 20, 2023Akebia Therapeutics to Present at Piper Sandler Healthcare Conference
Events & Presentations
November 28, 2023 at 10:30 AM EST
November 8, 2023 at 8:00 AM EST
September 11, 2023 at 9:30 AM EDT